99% Savings - Buy Just @1 Rs X
Metfine IPR is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Is the use of Metfine IPR safe for pregnant women?
Metfine IPR rarely shows harmful effects in in pregnant ladies. Even if it does, the effects are mild
Is the use of Metfine IPR safe during breastfeeding?
Metfine IPR may lead to some side effects in breastfeeding women. If you witness any unusal symptoms after taking Metfine IPR, discontinue its use and call your doctor right away. Follow your doctor's advice regarding the use of Metfine IPR.
What is the effect of Metfine IPR on the Kidneys?
Metfine IPR does not damage the kidneys.
What is the effect of Metfine IPR on the Liver?
Metfine IPR is not harmful for the liver.
What is the effect of Metfine IPR on the Heart?
Metfine IPR is completely safe for the heart.
Metfine IPR should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Metfine IPR unless your doctor advises you to do so -
Is this Metfine IPR habit forming or addictive?
Forming a habit of Metfine IPR has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can operate a vehicle or heavy machinery after taking Metfine IPR since it does not cause drowsiness.
Is it safe?
Yes, but take Metfine IPR only as per medical advice.
Is it able to treat mental disorders?
Metfine IPR is unable to treat or cure mental disorders.
Interaction between Food and Metfine IPR
Due to the absence of research, it is difficult to say how Metfine IPR and food will interact.
Interaction between Alcohol and Metfine IPR
Consuming Metfine IPR with alcohol can have many serious effects on your body.
Yes, Metfine IPR can cause low blood sugar (hypoglycemia). However, this can also occur if you delay or miss a meal, drink alcohol, exercise more than usual, can't eat due to stomach upset, and taking other antidiabetic medicine with metformin. So, regular monitoring of blood glucose level is needed and be cautious of symptoms of hypoglycemia, always keep glucose-rich food with you.
Metfine IPR is used with a proper diet and exercise program, to treat diabetes. It is also used with other medication to reduce the high blood sugar. It is used in a patient with type2 diabetes. It is also used in the treatment of polycystic ovarian syndrome (PCOS) and cancer.
Yes, Metfine IPR can cause night sweat, the exact mechanism of sweating is not known. But some research suggests that Metfine IPR causes hypoglycemia (low blood sugar) especially at night which can cause night sweats. Need to monitor your blood glucose level regularly, and talk to your doctor as your dose of Metfine IPR may need to be adjusted.
The long-term use can lead to the deficiency of Vitamin B12, which can further lead to megaloblastic anemia. Furthermore, Long-term Metformin use can also lead to kidney and liver problems.
Yes, Metfine IPR can cause some sleep problems, especially insomnia. On the other hand, Metfine IPR has proven to be useful for preventing sleep apnea. The exact relationship between Metfine IPR and sleep problems is still not clear, and further studies are needed for a clearer understanding.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826